[
  {
    "ts": null,
    "headline": "Why 2025 will be an inflection for Novo Nordisk, Eli Lilly's GLP-1s",
    "summary": "Weight-loss drugs have dominated the pharmaceutical market with their rapid success. Barclays head of European pharmaceuticals research, Emily Field, joins Seana Smith and Brad Smith on Morning Brief to discuss her outlook for the GLP-1 market in 2025: \"In terms of the inflection point for the market, you know, both Novo Nordisk (NVO) and Eli Lilly (LLY) have clinical catalysts that are scheduled throughout the year. But really, I think what is going to be important in terms of driving revenue upside and the impact sector-wide is just the prescription data ... [as] both companies have been investing billions in capacity expansion such that we think that we're probably going to really start to see the benefits of that here in 2025.\" Watch the video above for more about the analyst's expectations for the weight-loss drug space. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Naomi Buchanan.",
    "url": "https://finnhub.io/api/news?id=2cf77ae064988b78708cba347af96e547e84b679e5e7090e34f111137fc40993",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736186400,
      "headline": "Why 2025 will be an inflection for Novo Nordisk, Eli Lilly's GLP-1s",
      "id": 132290575,
      "image": "https://s.yimg.com/ny/api/res/1.2/iJ6s2L2SKsc8kUjU4G2Q3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/2ef84540-cc4f-11ef-b7d3-e4f72e0784fb",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weight-loss drugs have dominated the pharmaceutical market with their rapid success. Barclays head of European pharmaceuticals research, Emily Field, joins Seana Smith and Brad Smith on Morning Brief to discuss her outlook for the GLP-1 market in 2025: \"In terms of the inflection point for the market, you know, both Novo Nordisk (NVO) and Eli Lilly (LLY) have clinical catalysts that are scheduled throughout the year. But really, I think what is going to be important in terms of driving revenue upside and the impact sector-wide is just the prescription data ... [as] both companies have been investing billions in capacity expansion such that we think that we're probably going to really start to see the benefits of that here in 2025.\" Watch the video above for more about the analyst's expectations for the weight-loss drug space. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Naomi Buchanan.",
      "url": "https://finnhub.io/api/news?id=2cf77ae064988b78708cba347af96e547e84b679e5e7090e34f111137fc40993"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (NYSE:LLY) Among Israel Englander’s Top Stock Picks Heading Into 2025?",
    "summary": "We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stock picks. Israel Englander has always inspired the investment world by founding and managing the second-most profitable hedge […]",
    "url": "https://finnhub.io/api/news?id=cae25cf9f6e17bdec456932720f6d996d287717a61009a3428398e441e60fc56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736168747,
      "headline": "Is Eli Lilly and Company (NYSE:LLY) Among Israel Englander’s Top Stock Picks Heading Into 2025?",
      "id": 132290576,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stock picks. Israel Englander has always inspired the investment world by founding and managing the second-most profitable hedge […]",
      "url": "https://finnhub.io/api/news?id=cae25cf9f6e17bdec456932720f6d996d287717a61009a3428398e441e60fc56"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Down and Out. Opportunities Abound.",
    "summary": "Donald Trump’s election win prompted even more bullishness in a stock market that was already up significantly for the year.  For healthcare investors, though, it represented yet another reason to dump some stock.  Trump’s appointment of industry skeptics like  Robert F. Kennedy Jr.,  alongside broader expectations of a Republican crackdown on programs like Medicaid and Obamacare, has prompted a selloff in everything from hospitals to pharmaceuticals, health insurers and biotech.",
    "url": "https://finnhub.io/api/news?id=5ecfaab583f6fb045d9a38e85ba1f30c96ba7ed3da5389896f8a76e88f3a43da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736164800,
      "headline": "Healthcare Stocks Are Down and Out. Opportunities Abound.",
      "id": 132285420,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Donald Trump’s election win prompted even more bullishness in a stock market that was already up significantly for the year.  For healthcare investors, though, it represented yet another reason to dump some stock.  Trump’s appointment of industry skeptics like  Robert F. Kennedy Jr.,  alongside broader expectations of a Republican crackdown on programs like Medicaid and Obamacare, has prompted a selloff in everything from hospitals to pharmaceuticals, health insurers and biotech.",
      "url": "https://finnhub.io/api/news?id=5ecfaab583f6fb045d9a38e85ba1f30c96ba7ed3da5389896f8a76e88f3a43da"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential",
    "summary": "Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.",
    "url": "https://finnhub.io/api/news?id=871b8f850271e8941fb1a9beb6c513620f523b7934ebc1a942b6ca85d0cb8305",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736154000,
      "headline": "Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential",
      "id": 132286187,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/459047615/image_459047615.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.",
      "url": "https://finnhub.io/api/news?id=871b8f850271e8941fb1a9beb6c513620f523b7934ebc1a942b6ca85d0cb8305"
    }
  }
]